GLP-1 implant from Vivani Medical aims to help patients stay on treatment

Key Points:

• Vivani Medical is developing a semaglutide implant as a long-term maintenance treatment for obesity, aiming to help patients sustain weight loss by delivering the drug continuously over several months, potentially reducing side effects and improving adherence compared to weekly injections.
• The implant, a tiny titanium device inserted under the skin, would need to be replaced every six months or possibly annually, and is designed to provide steady drug release via a specialized membrane without mechanical parts.
• Early clinical trials are planned to assess safety, tolerability, and effectiveness, with the first human study expected to start in mid-2026; however, the implant is still several years from market availability and must overcome regulatory, clinical, and adoption challenges.
• Physicians express cautious optimism but highlight concerns including patient acceptance of implants, procedural training for providers, cost and insurance coverage uncertainties, and the need for comparative efficacy data versus existing GLP-1 treatments.
• If successful, the implant could address major issues with current GLP-1 therapies such as injection fatigue and discontinuation, potentially improving long-term obesity management and reducing healthcare costs linked to obesity-related conditions.